Skip to main content
SpringerLink
Log in

Bacterial Vaccines

  • Living reference work entry
  • First Online:
Book cover Cancer Therapeutic Targets

  • 211 Accesses

Abstract

A contemporary approach to bacterial cancer immunotherapy takes advantage of substantial progress in the understanding of the tumor-immune system interplay, as well as the recent advances in genetic engineering. Safe, targeted therapies are being developed, in which genetically-modified pathogens are designed to trigger effective anti-tumor immune response. Here we describe the bacterial strains intended for cancer immunotherapies, the genetic modifications that attenuate their pathogenicity but strengthen anti-tumor potential and the desirable mechanisms of actions. The only FDA approved Bacillus Calmette-Guerin-based cancer therapy as well as numerous examples of ongoing clinical trials involving different bacterial strains are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Bereta M, Hayhurst A, Gajda M, Chorobik P, Targosz M, Marcinkiewicz J, Kaufman HL. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine. 2007;25(21):4183–92. doi:10.1016/j.vaccine.2007.03.008.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky Jr TW. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A. 2004;101(38):13832–7. doi:10.1073/pnas.0406035101.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Chorobik P, Czaplicki D, Ossysek K, Bereta J. Salmonella and cancer: from pathogens to therapeutics. Acta Biochim Pol. 2013;60(3):285–97.

    CAS  PubMed  Google Scholar 

  • Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68. doi:10.1038/nri3175.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Galmbacher K, Heisig M, Hotz C, Wischhusen J, Galmiche A, Bergmann B, Gentschev I, Goebel W, Rapp UR, Fensterle J. Shigella mediated depletion of macrophages in a murine breast cancer model is associated with tumor regression. PLoS One. 2010;5(3):e9572. doi:10.1371/journal.pone.0009572.

    Article  PubMed Central  PubMed  Google Scholar 

  • Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'Addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23(28):6854–64. doi:10.1200/JCO.2005.17.186.

    Article  CAS  PubMed  Google Scholar 

  • Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe. 2014;15(3):295–305. doi:10.1016/j.chom.2014.02.003.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hong EH, Chang SY, Lee BR, Pyun AR, Kim JW, Kweon MN, Ko HJ. Intratumoral injection of attenuated Salmonella vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. Vaccine. 2013;31(10):1377–84. doi:10.1016/j.vaccine.2013.01.006.

    Article  CAS  PubMed  Google Scholar 

  • Kaimala S, Mohamed YA, Nader N, Issac J, Elkord E, Chouaib S, Fernandez-Cabezudo MJ, Al-Ramadi BK. Salmonella-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. Cancer Immunol Immunother. 2014;63(6):587–99. doi:10.1007/s00262-014-1543-x.

    Article  CAS  PubMed  Google Scholar 

  • Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol. 2014;65(2):267–9. doi:10.1016/j.eururo.2013.10.016.

    Article  PubMed Central  PubMed  Google Scholar 

  • Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013;104(1):22–7. doi:10.1111/cas.12075.

    Article  CAS  PubMed  Google Scholar 

  • Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.

    Article  CAS  PubMed  Google Scholar 

  • Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky Jr TW, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858–68. doi:10.1158/1078-0432.CCR-11-2121.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L. Predictive biomarkers of bacillus Calmette-Guerin immunotherapy response in bladder cancer: where are we now? Adv Urol. 2012;2012:232609. doi:10.1155/2012/232609.

    Article  PubMed Central  PubMed  Google Scholar 

  • Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene. 2010;29(29):4121–9. doi:10.1038/onc.2010.174.

    Article  CAS  PubMed  Google Scholar 

  • Massa PE, Paniccia A, Monegal A, de Marco A, Rescigno M. Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood. 2013;122(5):705–14. doi:10.1182/blood-2012-12-474098.

    Article  CAS  PubMed  Google Scholar 

  • Matzinger P. The evolution of the danger theory. Interview by Lauren Constable, Commissioning Editor. Expert Rev Clin Immunol. 2012;8(4):311–7. doi:10.1586/eci.12.21.

    Article  CAS  PubMed  Google Scholar 

  • Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 2003;10(10):737–44. doi:10.1038/sj.cgt.7700634.

    Article  CAS  PubMed  Google Scholar 

  • Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999;5(3):42–7.

    CAS  PubMed  Google Scholar 

  • Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319(1):47–65. doi:10.1111/nyas.12469.

    Article  CAS  PubMed  Google Scholar 

  • St Jean AT, Zhang M, Forbes NS. Bacterial therapies: completing the cancer treatment toolbox. Curr Opin Biotechnol. 2008;19(5):511–7. doi:10.1016/j.copbio.2008.08.004.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Tangney M. Gene therapy for cancer: dairy bacteria as delivery vectors. Discov Med. 2010;10(52):195–200.

    PubMed  Google Scholar 

  • Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol. 2009;16(1):96–103. doi:10.1128/CVI.00274-08.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Buttner P, Garbe C, Pawelec G. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or Melan-A-specific T cells. Clin Cancer Res. 2014;20(6):1601–9. doi:10.1158/1078-0432.CCR-13-2508.

    Article  CAS  PubMed  Google Scholar 

  • Wood LM, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol. 2014;4:51. doi:10.3389/fcimb.2014.00051.

    PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, 31-387, Poland

    Paulina Chorobik & Joanna Bereta

Authors
  1. Paulina Chorobik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joanna Bereta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanna Bereta .

Editor information

Editors and Affiliations

  1. Georgetown University Div. Hematology & Oncology, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this entry

Cite this entry

Chorobik, P., Bereta, J. (2014). Bacterial Vaccines. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_138-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-6613-0_138-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-6613-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation